Pioneer SCA3/MJD Translational Research Award

Introduction

The National Ataxia Foundation (NAF) was organized in 1957 in the state of Minnesota as a voluntary non-profit health organization. In its continuing efforts to find the cause, treatments, and cure for the ataxias, the National Ataxia Foundation (NAF) provides limited, short-term financial support of ataxia research.

NAF’s Research Grant Program funds only the best research proposals that are most likely to result in research breakthroughs that can be applied to diagnosis, better patient care, or treatments for people with ataxia.

The National Ataxia Foundation uses proposalCENTRAL to facilitate the grant application and review process. This document includes NAF policies and guidelines relevant to its research program. The instructions to submit a letter of intent and the full application is on the proposalCENTRAL website.

Description

The Pioneer SCA3/MJD Translational Research Award is for a research project that will facilitate the development of treatments for Spinocerebellar Ataxia Type 3/Machado Joseph Disease.

Funding will be for one year from March 1, 2022 to February 28, 2023. The total grant amount is $100,000. Indirect costs are not allowed to be paid from this grant award.

This award is meant for established ataxia researchers.

Guidelines

1. Indirect costs are prohibited from being applied to NAF grant awards.
2. Applicants for the Pioneer award must be established ataxia researchers.
3. Non-U.S. citizens are eligible to apply for a NAF grant award. Grant applications are accepted from U.S. and international institutions.
4. The National Ataxia Foundation will retain the right to unilaterally cancel any awards for non-compliance or non-performance.
5. Awards are not transferable.
6. No-cost extensions (NCE) will be considered for extenuating circumstances and require approval from NAF’s Research Director. Please submit requests for an NCE to beth@ataxia.org.

proposalCENTRAL

To utilize the proposalCENTRAL online portal to submit letters of intent and applications, a user account needs to be created. Use this weblink https://proposalcentral.com to create an account. Creating an account can be done any time prior to submitting a Letter of Intent to apply.
Letter of Intent

Using the proposalCENTRAL online portal (https://proposalcentral.com), please submit a full title and a scientific abstract of your research proposal, on or before October 5, 2021. You will receive an email when your Letter of Intent is approved, then you will be able to access the proposalCENTRAL portal to submit your application.

The primary purpose of the LOI abstract is to better understand the types of research projects that will be submitted to select and secure reviewers who are leaders in the ataxia field and have the particular focus and research acumen to review the final proposals that are submitted.

Submission of Application

Using the proposalCENTRAL online portal, please submit the full application on or before November 2, 2021. The term of the proposed project should be from March 1, 2022, to February 28, 2023. The full application will require basic information and the following attachments:

- Lay Summary
- Scientific Abstract
- Budget Details
- Background and Significance (1 page maximum)
- Biosketch
- Literature Cited
- Preliminary Studies (1 page maximum)
- Publication List
- Research Plan (3 page maximum)
- Signed Signature Pages
- Summary of Specific Aims (1 page maximum)
- Institutional banking instructions for domestic or international partners

Review Dates

Review by Medical Research Advisory Board takes place late December through early January.

Written notification of awards will be sent in late February 2022. Please do not call or email NAF about the status of your grant application.

Review Process

All applications are reviewed and evaluated by a review committee, selected by NAF’s Research Director. Members of NAF’s Medical and Research Advisory Board participate in the review. The review committee will score and prioritize all grants received by the deadline and make funding recommendations. The NAF Board of Directors will consider the recommendations and make the final approval and funding determinations.

Funding of awards is based on availability of funds, the priority score assigned to each application, the relevance to SCA3/MJD, innovation, and the translational aspect of the research project. Applications with high scores in relevance to ataxia, and scientific merit and translational aspect will receive higher priority.

Disbursement of Funds

Awards are for one year only. Checks or electronic transfers will be issued in February and sent directly to the institution of the funded researcher named in the application. Electronic payment is preferred.
Non-funded applicants will also be notified in February.

**Change in Status of Awarded**

Awards are to remain solely with the designated awardee and may not be transferred to any other personnel. If a recipient decides not to continue work in ataxia research, the award will be terminated. In the event that NAF terminated an award, the award amount will be pro-rated for the number of months it was in effect, and the pro-rated unused funds shall be returned to NAF. If an investigator changes institutions, the award may be transferred, contingent upon the successor institution’s commitment to support the research for the full remaining term of the award.

**Publications**

When a paper or poster is published or presented before a scientific organization by an awardee, based on the work supported by an NAF grant, an electronic copy of the paper or a description of the presentation should be sent to the National Ataxia Foundation. All papers, posters and press releases shall carry a credit line to the National Ataxia Foundation. In addition, a copy of any press release regarding the study funded by NAF should also be e-mailed to NAF at beth@ataxia.org.

**Reports**

A final scientific report and lay summary is to be submitted to the National Ataxia Foundation within four (4) months of completion of the research project. The scientific report is reviewed by NAF’s Medical Research Advisory Board but is not made public.

Because the National Ataxia Foundation takes seriously its responsibility to report to its members on the use of their research contributions, the layperson final summary will be shared with the organization’s members and posted on NAF’s website. The summary must be written in such a manner as to be understood by the average layperson and should not contain privileged or unpublished information.

A full financial report detailing how grant award funds were utilized is due 4 months after end of project.

**Definitions**

**Indirect Costs:** Indirect costs (sometimes known as Facilities and Administrative costs) are defined as costs incurred when conducting or supporting research and service, but which cannot be readily identified as benefiting particular research projects. Examples of indirect costs include, but are not limited to:

- Plant operation and maintenance: utilities, janitorial services, routine maintenance and repairs, etc.
- Depreciation or use allowance: for buildings and equipment
- General administration and general expense: accounting, payroll, administrative offices, etc.
- Sponsored project administration: personnel and other costs of offices whose responsibility is the administration of sponsored projects
- Departmental administration expenses: administrative costs at the college and departmental levels

**NAF Communication Outlets**

The title of each study funded by NAF, the name of the principal investigator, institution, city, and state will be published on our web page, in our newsletter, annual report, social media pages, and wherever NAF feels appropriate.

Each grant application must include a lay summary that will be used to show donors how their contributions to research has enhanced our understanding of ataxia. Lay summaries will be published in NAF communication channels and should not contain confidential information. The other parts of the grant application are considered confidential and will only be released to members of NAF’s Medical Research Advisory Board members, the review committee, NAF staff and NAF Board of Directors.